Decapeptyl

Phase 2Small molecule

SSheba Medical Center

Decapeptyl is one of 37 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerRecruiting

Luteal Phase SupportUnknown status

OocyteCompleted

Prostate CancerPhase 2

Recruiting

Luteal Phase SupportPreclinical

Unknown status

OocytePreclinical

Completed

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Nizoral

WWim Janssens

Phase 3

21 3

Acetylsalicylic Acid

Bayer

Phase 3

2 4

Perflutren Lipid Microspheres

SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Phase 3

1 5

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 6

Decapeptyl

SSheba Medical Center

Phase 2

2 7

Trexall

Jazz Pharmaceuticals

Preclinical

—8

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 9

Duragesic

CCephalon

Preclinical

1 10

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Prostate Cancer

NCT05557604

Q4 2030

Phase 2/3Recruiting

Prostate Cancer

NCT06282588

Clinical

Trials by Indication[1]

Ovarian2 trials

GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response

Unknown status·SSheba Medical Center·N/A·NCT02144818·60 enrolled

Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response

Unknown status·NNavy General Hospital, Beijing·N/A·NCT02940535·200 enrolled

Luteal Phase Support2 trials

Luteal Phase Support In IVF Women Using GnRH Agonist

Completed·NNational University of Malaysia··NCT04174378·222 enrolled

Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS

Unknown status·MMeir Medical Center·N/A·NCT02827656·50 enrolled

Prostate Cancer2 trials

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting·CCancer Research Antwerp·Phase 2/3·NCT06282588·493 enrolled

Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer

Recruiting·RRegina Elena Cancer Institute·Phase 2·NCT05557604·146 enrolled

Ovarian Hyperstimulation1 trial

Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation

Completed·KKasr El Aini Hospital·Phase 3·NCT02342197·60 enrolled

GnRH Antagonist1 trial

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

Completed·—·Phase 3·NCT04537078·90 enrolled

3 more indications

Oocyte Retrieval1 trial

Evaluation of Time Interval Between Ovulation Trigger With Triptorelin Acetate and Oocyte Retrieval

Completed·IInstituto de Investigacion Sanitaria La Fe·Phase 2·NCT02244151·130 enrolled

Oocyte1 trial

Follicle Size and Oocyte Development

Completed·SSheba Medical Center·N/A·NCT03660813·200 enrolled

Trial1 trial

Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

Completed·AAZ Jan Palfijn Gent·Phase 4·NCT01607203·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Decapeptyl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Decapeptyl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Decapeptyl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheba Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSheba Medical Center

Decapeptyl

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2030

Trials by Indication[1]

Ovarian2 trials

Luteal Phase Support2 trials

Prostate Cancer2 trials

Ovarian Hyperstimulation1 trial

GnRH Antagonist1 trial

Oocyte Retrieval1 trial

Oocyte1 trial

Trial1 trial

References

Drug Info

Quick Facts

Related News